Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study

References

• Lehto M, Haukka J, Aro A, et al. Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland. Open Heart. 2022;9(2):e002140. doi: 10.1136/openhrt-2022-002140.
   PubMed Web of Science ®Google Scholar
• Björck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103–3108. doi: 10.1161/STROKEAHA.113.002329.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0.
   PubMed Web of Science ®Google Scholar
• Hallinen T, Soini EJ, Asseburg C, et al. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data. BMJ Open. 2014;4(2):e004071. doi: 10.1136/bmjopen-2013-004071.
   PubMed Web of Science ®Google Scholar
• Hallinen T, Soini E, Asseburg C, et al. Cost-Effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with non-valvular atrial fibrillation. Clin Outcomes Res. 2021;13:745–755.
   PubMed Web of Science ®Google Scholar
• Wong ES, Done N, Zhao M, et al. Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees. J Manag Care Spec Pharm. 2021;27(8):1056–1066. doi: 10.18553/jmcp.2021.27.8.1056.
   PubMed Web of Science ®Google Scholar
• Grymonprez M, Simoens C, Steurbaut S, et al. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace. 2022;24(6):887–898. doi: 10.1093/europace/euab303.
   PubMed Web of Science ®Google Scholar
• Teppo K, Airaksinen KEJ, Jaakkola J, et al. Trends in treatment and outcomes of atrial fibrillation during 2007–17 in Finland. Eur Heart J Qual Care Clin Outcomes. 2023;9(7):673–679. doi: 10.1093/ehjqcco/qcac086.
   PubMed Web of Science ®Google Scholar
• Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2022;11(13):3788. doi: 10.3390/jcm11133788.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
   PubMed Web of Science ®Google Scholar
• Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12(1):14. doi: 10.1186/1477-9560-12-14.
   PubMedGoogle Scholar
• Lehto M, Niiranen J, Korhonen P, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry: quality of warfarin therapy. Pharmacoepidemiol Drug Saf. 2017;26(6):657–665. doi: 10.1002/pds.4194.
   PubMed Web of Science ®Google Scholar
• Vestergaard AS, Skjøth F, Larsen TB, et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLOS One. 2017;12(11):e0188482. doi: 10.1371/journal.pone.0188482.
   PubMed Web of Science ®Google Scholar
• Carmo J, Ferreira J, Costa F, et al. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: a meta-analysis of randomized trials. Int J Cardiol. 2017;244:196–201. doi: 10.1016/j.ijcard.2017.06.004.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983. doi: 10.1016/S0140-6736(10)61194-4.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127(22):2166–2176. doi: 10.1161/CIRCULATIONAHA.112.142158.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF Trial. J Am Heart Assoc. 2014;3(2):e000521. doi: 10.1161/JAHA.113.000521.
   PubMed Web of Science ®Google Scholar
• Lixiana; 2024. Available from: http://lixiana-epar-public-assessment-report_en.pdf
   Google Scholar
• Ho C-W, Ho M-H, Chan P-H, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015;46(1):23–30. doi: 10.1161/STROKEAHA.114.006476.
   PubMed Web of Science ®Google Scholar
• Chan Y-H, Lee K-T, Kao Y-W, et al. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. PLOS One. 2019;14(3):e0213517. doi: 10.1371/journal.pone.0213517.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725. doi: 10.1161/JAHA.116.003725.
   PubMed Web of Science ®Google Scholar
• Lehto M, Halminen O, Mustonen P, et al. The nationwide Finnish AntiCoagulation in Atrial Fibrillation (FinACAF): study rationale, design, and patient characteristics. Eur J Epidemiol. 2022;37(1):95–102. doi: 10.1007/s10654-021-00812-x.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Cannegieter SC, Meer FJM, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239. doi: 10.1055/s-0038-1651587.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin. Chest. 2013;144(5):1555–1563. doi: 10.1378/chest.13-0054.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800–804. doi: 10.1097/EDE.0b013e3181577654.
   PubMed Web of Science ®Google Scholar
• Själander S, Sjögren V, Renlund H, et al. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res. 2018;167:113–118. doi: 10.1016/j.thromres.2018.05.022.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49(12):2933–2944. doi: 10.1161/STROKEAHA.118.020232.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189. doi: 10.1136/bmj.i3189.
   PubMed Web of Science ®Google Scholar
• Rutherford O-CW, Jonasson C, Ghanima W, et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):75–85. doi: 10.1093/ehjcvp/pvz086.
   PubMed Web of Science ®Google Scholar
• Liu F, Yang Y, Cheng W, et al. Reappraisal of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:757188. doi: 10.3389/fcvm.2021.757188.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48(9):2494–2503. doi: 10.1161/STROKEAHA.117.017549.
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;2005(3):CD001927. doi: 10.1002/14651858.CD001927.pub2.
   PubMedGoogle Scholar
• Smith J, Forster A, House A, et al. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;2007(3):CD001919. doi: 10.1002/14651858.CD006186.pub2.
   Google Scholar
• Zhang J, Wang X, Liu X, et al. Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. Eur J Epidemiol. 2021;36(8):793–812. doi: 10.1007/s10654-021-00751-7.
   PubMed Web of Science ®Google Scholar
• Rapola JM, Virtamo J, Korhonen P, et al. Validity of diagnoses of major coronary events in national registers of hospital diagnoses and deaths in Finland. Eur J Epidemiol. 1997;13(2):133–138. doi: 10.1023/a:1007380408729.
   PubMed Web of Science ®Google Scholar
• Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health. 2012;40(6):505–515. doi: 10.1177/1403494812456637.
   PubMed Web of Science ®Google Scholar